Submission of Annual Secretarial Compliance Report for the financial year ended 31 March 2025 (2024-25).
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tatva Chintan Pharma Chem Ltd has filed its Annual Secretarial Compliance Report for the financial year ended 31 March 2025, as required under Regulation 24A of SEBI's Listing Regulations. The report, prepared by M/s TNT & Associates, Practicing Company Secretaries (Vadodara), confirms that the company has complied with all applicable SEBI regulations, circulars, and secretarial standards during the review period. No non-compliances, deviations, or penalties were observed, and no prior observations from previous reports remained pending. All key areas including related party transactions, insider trading, director qualifications, policy adoption, website disclosures, and performance evaluation were found to be in order.
This is a routine annual compliance filing with no adverse findings, which signals good corporate governance and regulatory standing. No material impact on shareholders or stock price is expected from this disclosure.